Navigation Links
Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 27th Annual J.P. Morgan Healthcare Conference. The details are as follows:

    Date:  Monday, January 12, 2009
    Time:  8:00 a.m. - 8:30 a.m. Pacific
    Location: Westin St. Francis, San Francisco, California

    Webcast link:
http://metameetings.com/webcasts/jpmorgan/healthcare09/directlink?ticker=OREX

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Prime Therapeutics Hires Steven Blumenfield as Chief Marketing Officer
3. Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
4. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
5. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
6. Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
7. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
8. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
9. Transition Therapeutics Announces Dates for Upcoming Corporate Events
10. Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
11. Precision Therapeutics Secures $43 Million in Venture Capital Funding
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 2Health News:Nutra Pharma Completes FDA Submission for Nyloxin OTC and Nyloxin Rx -- Over-the-Counter and Prescription Treatments for Chronic Pain 3Health News:Hormonal Drugs Cool Hot Flashes From Prostate Cancer Therapy 2Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 2Health News:Interleukin Genetics Receives Approval To Sell its PST(R) Periodontal Disease Genetic Test in New York 3
Other Medicine News:Health News:Few Countries on Track to Curb Maternal, Child Mortality Rates 2Health News:Few Countries on Track to Curb Maternal, Child Mortality Rates 3Health News:Samplify Systems Announces Availability of Samplify for Windows Release 2.6, and Samplify for Windows Embedded Edition, Transforming RF Data Recording Applications with X-COM Systems 2Health News:Samplify Systems Announces Availability of Samplify for Windows Release 2.6, and Samplify for Windows Embedded Edition, Transforming RF Data Recording Applications with X-COM Systems 3Health News:Grubb & Ellis Healthcare REIT Names Danny Prosky Executive Vice President, Acquisitions 2Health News:Grubb & Ellis Healthcare REIT Names Danny Prosky Executive Vice President, Acquisitions 3Health News:North America Primed for Pet Insurance Market Expansion and Expecting $1.1 Billion by 2012 2Health News:UHW Unveils Proposals for SEIU Convention 2